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Abstract: Bone tissue engineering scaffolds should be
designed to optimize mass transport, cell migration, and
mechanical integrity to facilitate and enhance new bone
growth. Although many scaffold parameters could be modi-
fied to fulfill these requirements, pore size is an important
scaffold characteristic that can be rigorously controlled with
indirect solid freeform fabrication. We explored the effect of
pore size on bone regeneration and scaffold mechanical
properties using polycaprolactone (PCL) scaffolds designed
with interconnected, cylindrical orthogonal pores. Three
scaffold designs with unique microarchitectures were fabri-
cated, having pore sizes of 350, 550, or 800 lm. Bone mor-
phogenetic protein-7 transduced human gingival fibroblasts
were suspended in fibrin gel, seeded into scaffolds, and
implanted subcutaneously in immuno-compromised mice
for 4 or 8 weeks. We found that (1) modulus and peak stress
of the scaffold/bone constructs depended on pore size and
porosity at 4 weeks but not at 8 weeks, (2) bone growth
inside pores depended on pore size at 4 weeks but not at 8
weeks, and (3) the length of implantation time had a limited
effect on scaffold/bone construct properties. In conclusion,
pore sizes between 350 and 800 lm play a limited role in
bone regeneration in this tissue engineering model. There-
fore, it may be advantageous to explore the effects of other
scaffold structural properties, such as pore shape, pore
interconnectivity, or scaffold permeability, on bone regener-
ation when designing PCL scaffolds for bone tissue engi-
neering.  2009 Wiley Periodicals, Inc. J Biomed Mater Res
92A: 359–368, 2010
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INTRODUCTION
Tissue engineering scaffolds have been used to
support regeneration of many tissue types, such as
bone, cartilage, vasculature, ligament, nerve, and
skin.1–6 Scaffold properties vary from tissue to tissue,
as each has unique mechanical and biochemical prop-
erties. A highly porous scaffold with an intercon-
nected pore network is necessary to mediate nutrient
and waste diffusion and to ultimately allow con-
nected tissue growth.7,8 The scaffold design should
also incorporate a microarchitecture that yields an
adequate amount of mechanical strength to carry
load at the implantation site until new, load-bearing
tissue is formed.7 Scaffold parameters may be varied
to meet these requirements. In addition, scaffolds
must be biocompatible, osteoconductive, and/or
osteoinductive. Osteoconductive scaffolds facilitate
cell attachment, proliferation, and differentiation.7,8
Scaffolds with osteoinductive properties enhance new
tissue growth, for example, by delivery of biofactors.7
The pore size of a tissue engineering scaffold is an
important parameter that affects the quantity and
characteristics of new tissue formation.9 An optimal
pore size for bone tissue engineering scaffolds is not
well defined. Pore sizes of 10–2250 lm have been
used in bone tissue engineering scaffolds resulting in
varying degrees of tissue in-growth.10–15,16 Pore sizes
between 100 and 400 lm are proposed as optimal
for osteoconduction,17 and pore sizes greater than
300 lm are recommended to enhance bone formation
via vascularization.9 Pore sizes smaller than 100 lm
may not be sufficient in terms of mass transport and
cell migration and may induce endochondral carti-
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lage formation before osteogenesis occurs.9 Larger
pore sizes may result in excessive void space and
compromise the mechanical properties of the scaf-
fold; however, larger pore sizes are favorable for
capillary formation, which leads to direct osteogene-
sis.9 Therefore, the scaffold pore size must be small
enough to ensure mechanical integrity, but large
enough to fulfill the nutrient and waste diffusion
needs of the tissue. Along with pore size, many other
scaffold characteristics and experimental design varia-
bles are also important in new tissue formation. These
include porosity, permeability, pore interconnectivity,
pore shape, mechanical properties, biomaterial, fabri-
cation method, implant location, animal model, and
use of cells and biofactors.7,8,10–12,17–19
Polycaprolactone (PCL) is a biocompatible, semi-
crystalline, slowly-degrading polymer used in several
tissue engineering applications including bone7,8,12,15,20–23
and cartilage.24–27 Although PCL is not osteoconductive,
it can be modified to increase osteoconductive and
osteoinductive potential. For example, a PCL scaffold
may be manufactured with growth factors and/or cells
attached to the scaffold surface, or transduced cells and/
or growth factors may be seeded into the scaffold before
implantation.7,11,12,18–20
We previously demonstrated bone tissue in-
growth on PCL and polypropylene fumarate/b-tri-
calcium phosphate (PPF/b-TCP) scaffolds with pore
sizes of 1.75–2.25 mm12 and 300 or 800 lm,19 respec-
tively in a subcutaneous mouse model. The objective
of this study was to evaluate the effect of PCL scaf-
fold pore sizes, between 350 and 800 lm, on bone
regeneration and scaffold mechanical properties in
the same tissue engineering model.
MATERIALS AND METHODS
Scaffold design
Scaffolds with interconnected, cylindrical orthogonal
pores were designed using custom Interactive Data
LanguageTM programs (IDL; Research Systems, Boulder,
CO). Three PCL scaffold designs were investigated in this
study. First, we designed scaffolds for subcutaneous im-
plantation into immuno-compromised mice (hereafter
referred to as ‘‘subcutaneous’’ scaffolds). We designed three
subcutaneous scaffolds with distinct microarchitectures: (1)
pore size of 350 lm and strut diameter of 350 lm, (2) pore
size of 550 lm and strut diameter of 600 lm, and (3) pore
size of 800 lm and strut diameter of 900 lm. The global sub-
cutaneous scaffold shape was cylindrical (5 mm in diameter
and 3 mm in height) and identical for each scaffold. Figure 1
shows lCT renderings of the three fabricated subcutaneous
PCL scaffold designs.
Second, we designed PCL scaffolds to test bulk mechan-
ical properties of the three subcutaneous scaffold designs
(hereafter referred to as ‘‘mechanical testing’’ scaffolds).
Mechanical testing scaffolds had the same microarchitec-
tures as subcutaneous scaffolds, but the global cylindrical
shape of mechanical testing scaffolds was larger (8 mm in
diameter and 16 mm in height). The mechanical testing
scaffolds satisfied the 2:1 aspect ratio requirement of the
ASTM compression testing standard for rigid plastics
(ASTM D695-02a).
Third, we designed solid PCL cylinders to test bulk me-
chanical properties of melt cast PCL. The global shape of
the solid cylinders was cylindrical (8 mm in diameter and
16 mm in height). The solid cylinders satisfied the 2:1 as-
pect ratio requirement of the ASTM compression testing
standard for rigid plastics (ASTM D695-02a).
Scaffold fabrication
An indirect solid free-form fabrication (SFF) technique
was utilized to build subcutaneous scaffolds in a layer-by-
layer additive process.7,28 Molds were built on a 3D Solid-
Scape (SolidScape, Merrimack, NH) printer and were made
of a thermoplastic (melting temperature of 1208C) and a
waxy material comprised of natural and synthetic wax and
fatty esters (melting temperature of 788C). The wax was
melted in a vacuum oven (Fisher Scientific, Pittsburgh, PA)
leaving intact thermoplastic molds. A hydroxyapatite (HA)
slurry suspension (hydroxyapatite powder [Plasma Biotal,
Tideswell, North Derbyshire, UK] used as-received, ben-
zoyl peroxide [BPO], N,N-dimethyl p-toluidine [NMP], and
acetone) was cast into thermoplastic molds at room tem-
perature. HA molds were sintered at 13008C with a 1 h
dwell time and were furnace cooled.
Next, HA molds were cast into melted PCL. e-PCL pow-
der (CAPA 6501, Solvay Caprolactones, Warrington,
Cheshire, UK; melting temperature of 608C, molecular
weight of 50 kDa, and particle size distribution in the
range of 10–100 lm) was packed into 6-mm diameter wells
in a Teflon1 casting mold. e-PCL powder was melted in a
vacuum oven which had been heated to 1208C and
allowed to equilibrate. A 220 inHg vacuum was pulled
immediately, maintained for 90 min, and slowly released.
HA molds were gently pushed into the melted PCL, and
the entire construct was placed into the vacuum oven at
1208C. A 220 inHg vacuum was pulled immediately,
maintained for 30 min, slowly released, and the constructs
were allowed to cool to room temperature. After melt cast-
ing was complete, HA was removed using RDO Rapid
Decalcifier (APEX Engineering Products, Plainfield, IL)
leaving intact PCL scaffolds. PCL scaffolds were rinsed
with water and 70% ethanol and were stored in 70% etha-
nol until cell seeding. Figure 2 describes a summary of the
fabrication process used to create subcutaneous scaffolds.
Mechanical testing scaffolds were manufactured using
the indirect SFF casting method described previously.
However, a Teflon casting mold with 9-mm diameter wells
was used to PCL melt cast mechanical testing scaffolds.
Figure 2 describes a summary of the fabrication process
used to create mechanical testing scaffolds.
Solid PCL cylinders were fabricated using the following
method. e-PCL powder was packed into 9-mm diameter
wells in a Teflon casting mold. e-PCL powder was melted
in a vacuum oven which had been heated to 1208C and
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allowed to equilibrate. A vacuum of 220 inHg was pulled
immediately, maintained for 75 min, and slowly released.
Teflon tubing (9 mm outer diameter, 8 mm inner diameter)
was gently pushed into melted PCL to eliminate air bub-
bles on the exterior of the casting well. Melted PCL cooled
to room temperature, and tubing was removed leaving
solid PCL cylinders intact. Table I summarizes how subcu-
taneous scaffolds, mechanical testing scaffolds, and solid
PCL cylinders were utilized.
Presurgical subcutaneous scaffold assessment
All subcutaneous scaffolds were scanned in air using an
MS8X-130 high-resolution lCT scanner (GE Medical Sys-
tems, Toronto, CAN) with 28 lm voxel resolution at 75 kV
and 75 mA. GEMS Microview software (GE Medical Sys-
tems, Toronto, CAN) was used to verify scaffold pore size
and calculate scaffold porosity. A threshold of 2600 ADU
defined the lower limit for PCL.
Mechanical testing scaffold assessment
Mechanical testing scaffolds were scanned with lCT
and analyzed as described previously. Four wet scaffolds
(soaked in water for 20 min) were mechanically tested in
compression for each microarchitecture. The specimens
were tested to failure (or to a maximum of 40% strain) in
the z-direction between a rigid and flexible steel platen at
a rate of 1 mm/min. TestWorks4 software (MTS Systems,
MN) was used to generate data.
Solid PCL cylinder assessment
Solid cylinders were scanned with lCT as described
previously to ensure that no large air bubbles were
present. Four wet cylinders (soaked in water for 20 min)
were mechanically tested in compression as described
previously.
Cell seeding and implantation
Primary human gingival fibroblasts were prepared from
explants of human surgical waste in accordance with the
University of Michigan Institutional Review Board. Pas-
sage 11 human gingival fibroblasts were infected with
AdCMV-BMP-7, a first generation recombinant adenovirus
Figure 2. Summary of the indirect solid free-form fabrica-
tion (SFF) process used to create subcutaneous PCL scaf-
folds and mechanical testing PCL scaffolds. [Color figure
can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
Figure 1. lCT renderings of subcutaneous scaffolds (prior to implantation) with three distinct microarchitectures. [Color
figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
PCL SCAFFOLD PORE SIZE HAS LIMITED INFLUENCE ON BONE REGENERATION 361
Journal of Biomedical Materials Research Part A
construct expressing the murine BMP-7 gene under a cyto-
megalovirus (CMV) promoter. Cells were suspended in 5
mg/mL fibrinogen. Sixty microliters of fibrinogen/cell sus-
pension, containing 1.5 million cells, was pipette into
each of 42 subcutaneous scaffolds (n 5 14 for each micro-
architecture; hereafter referred to as ‘‘seeded’’ scaffolds).
Three microliters of thrombin was added to each seeded
scaffold to create fibrin gel and encapsulate cells. Sixty lL
of fibrinogen suspension, containing no cells, was pipette
into each of 24 subcutaneous scaffolds (n 5 8 for each
microarchitecture; hereafter referred to as ‘‘control’’ scaf-
folds). Three microliters of thrombin was added to each
control scaffold to create fibrin gel.
Seeded and control scaffolds were implanted subcutane-
ously into 5- to 8-week old immuno-compromised mice
(N:NIH-bg-nu-xid, Charles River, Wilmington, MA). Ani-
mals were anesthetized with ketamine and xylazine (50
and 5 mg/g, respectively). Four subcutaneous pockets
were created dorsally (two on each side of the spine), one
scaffold was implanted into each pocket, and surgical sites
were closed with wound clips. Both seeded and control
scaffolds were implanted into each animal, and scaffold
implant location was randomized. Half of the scaffolds (n
5 21 seeded scaffolds, n 5 12 control scaffolds) were eval-
uated after 4 weeks in vivo, and the remainder were eval-
uated after 8 weeks in vivo. NIH guidelines for the care
and use of laboratory animals (NIH Publication no. 85-23
Rev. 1985) have been observed. Surgical procedures and
protocols were in compliance with University Committee
on Use and Care of Animals regulations.
Seeded scaffold/tissue construct assessment
After 4 or 8 weeks in vivo, mice were euthanized and all
scaffolds were removed, placed into Z-Fix (Anatech, Battle
Creek, MI) overnight, and stored in 70% ethanol. Seeded
scaffolds were scanned in water in an MS8X-130 high-reso-
lution lCT scanner to characterize newly formed tissue.
Control scaffolds were scanned to verify that no mineral-
ized tissue was formed inside the pores or around the
scaffold exterior. GEMS Microview software was used to
analyze lCT data. A threshold of 1100 ADU defined the
lower limit for mineralized bone tissue.
Scaffolds used for histological evaluation (n 5 12, n 5 4
for each microarchitecture) were demineralized with RDO
Rapid Decalcifier, sectioned, and stained with hematoxylin
and eosin (H&E). The remaining seeded (n 5 30, n 5 10
for each microarchitecture) and control (n 5 24, n 5 8 for
each microarchitecture) scaffolds were mechanically tested
in compression as described previously. The control
scaffolds served as controls for histology and mechanical
testing.
Statistical analysis
Data are expressed as mean 6 standard deviation for
each parameter. SPSS 15.0.1 (SPSS, Chicago, IL) was used
to perform one-way ANOVA and independent sample t-
tests. A p-value < 0.05 was considered significant.
RESULTS
Table II defines the lCT and mechanical testing
parameters evaluated in this study. We assessed (1)
the effect of scaffold pore size on bone regeneration
and mechanical properties, (2) the effect of cells on
scaffold mechanical properties, and (3) the effect of
TABLE I
Summary of All Fabricated Subcutaneous Scaffolds, Mechanical Testing Scaffolds, and Solid PCL Cylinders
Subcutaneous Scaffolds
Mechanical Testing
Scaffolds Solid PCL Cylinders
Global dimensions 5 mm diameter 8 mm diameter 8 mm diameter
3 mm height 16 mm height 16 mm height
Microarchitectures Pore sizes of 350 lm,
550 lm, or 800 lm
and respective strut
diameters of 350 lm,
600 lm, or 900 lm
Pore sizes of 350 lm,
550 lm, or 800 lm
and respective strut
diameters of 350
lm, 600 lm, or 900
lm
Solid PCL
Total fabricated n 5 66 (n 5 22 for
each microarchitecture)
n 5 12 (n 5 4 for each
microarchitecture)
n 5 4
lCTa n 5 66 (n 5 22 for each
microarchitecture)
n 5 12 (n 5 4 for each
microarchitecture)
n 5 4
Implanted with cells (histology) n 5 12 (n 5 4 for each
microarchitecture)
Not implanted Not implanted
Implanted with cells (mechanical testing) n 5 30 (n 5 10 for each
microarchitecture)
Not implanted Not implanted
Implanted without cells (mechanical testing
and histology control)
n 5 24 (n 5 8 for each
microarchitecture)
Not implanted Not implanted
Not implanted (bulk mechanical properties) N/A n 5 12 (n 5 4 for each
microarchitecture)
n 5 4
aAll subcutaneous scaffolds were evaluated with lCT prior to implantation.
Mechanical testing scaffolds and solid PCL cylinders were not implanted.
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scaffold implantation time on bone regeneration and
scaffold mechanical properties.
Effect of scaffold pore size on bone regeneration
and mechanical properties
Bone grew inside the pore space and formed a
cortical shell around the exterior of all seeded scaf-
folds. Figure 3 shows H&E staining of bone within
the pores of seeded scaffolds 4 and 8 weeks after im-
plantation. Figure 4a shows a lCT rendering of a
550-lm seeded scaffold implanted for 4 weeks sur-
rounded by bone. Figure 4(b) shows a lCT cross-sec-
tion of a 550-lm seeded scaffold implanted for 4
weeks. The scaffold/bone construct can be viewed
from the x-, y-, and z-directions, and bone is visible
within the pores and outside the scaffold. BMD
of tissue formed after 4 and 8 weeks in vivo was
within the normal range of those for human trabecu-
lar and cortical bone, 120–1100 mg/cm3, respec-
tively.29 Compressive modulus of the scaffold/bone
construct was within the lower range of normal
human trabecular bone.30
The majority of new bone formed outside the scaf-
fold, but some mineralized tissue grew within the
scaffold pores as well (Table III). After 4 weeks,
scaffold bone volume was significantly greater in
800-lm scaffolds than in 350-lm scaffolds. Also,
modulus and peak stress in 350-lm scaffolds were
significantly greater than in 550- and 800-lm scaf-
folds. After 8 weeks, there were no statistical differ-
TABLE II
Definition of Variables Measured with lCT and Mechanical Testing
Parameters Definition
lCT Parameters
Scaffold volume fraction Percentage of the scaffold that contains PCL
Scaffold porosity Percentage of scaffold void space
Total bone volume Volume of mineralized tissue that grew within the scaffold pore space and
outside of the scaffold
Scaffold bone volume Volume of mineralized tissue that grew within the scaffold pore space
Total bone mineral density (BMD) BMD of mineralized tissue that grew within the scaffold pore space and
outside of the scaffold
Scaffold bone mineral density (BMD) BMD of the mineralized tissue that grew within the scaffold pore space
Scaffold bone volume fraction (BVF) Percentage of the scaffold pore space filled with mineralized tissue
Mechanical Testing Parameters
Modulus Compressive Young’s modulus
Peak stress Peak stress achieved during compressive loading
Figure 3. H&E staining of seeded scaffolds of each microarchitecture 4 and 8 weeks after implantation. Pore space (filled
with tissue) and scaffold are labeled in the upper left image, and labeling applies similarly to all images. Magnification for
all images is 35. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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ences between the three architectures in either the
amount of bone formed or mechanical properties. It
is important to note that scaffold porosity varied
for each scaffold microarchitecture. Thus, scaffold
porosity may have affected the results (see Discus-
sion section).
Pore size did not affect bulk mechanical properties
of mechanical testing scaffolds. Modulus of 350, 550,
and 800 lm mechanical testing scaffolds was 315.09
6 49.77, 246.33 6 43.72, and 298.61 6 30.80 MPa,
respectively. Peak stress of 350, 550, and 800 lm me-
chanical testing scaffolds was 7.07 6 5.34, 3.40 6
3.01, and 6.30 6 3.32 MPa, respectively. The peak
stress of mechanical testing scaffolds was similar to
the peak stress in seeded and control subcutaneous
scaffolds. The modulus and peak stress of solid PCL
cylinders were 645.88 6 56.44 and 14.33 6 7.34 MPa,
respectively.
Effect of cells on scaffold mechanical properties
Table IV shows the effect of cells on scaffold me-
chanical properties after 4 and 8 weeks of implanta-
tion. At 4 weeks, the modulus of 550 and 800 lm
seeded scaffolds was significantly decreased com-
pared to control scaffolds. At 8 weeks, the modulus
of 550 lm seeded scaffolds was significantly
decreased compared to control scaffolds.
Figure 4. (a) lCT rendering of a 550-lm seeded scaffold 4 weeks after implantation. The majority of new bone (white)
grew outside the scaffold (green) and formed a cortical shell. (b) lCT cross-section of a 550-lm seeded scaffold 4 weeks
after implantation. Bone is seen within the scaffold pores and outside the scaffold. [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.com.]
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Effect of scaffold implantation time on bone
regeneration and mechanical properties
Table V shows the effect of scaffold implantation
time on bone regeneration and mechanical properties
in seeded scaffolds. Total BMD for 550- and 800-lm
seeded scaffolds was significantly increased 8 weeks
after implantation compared to 4 weeks. All other
parameters were unaffected by scaffold implantation
time.
DISCUSSION
The pore size of a tissue engineering scaffold is
thought to influence the quantity and characteristics
of newly forming tissue.9 However, in our tissue en-
gineering model, pore size had a limited influence
on new bone formation and scaffold mechanical
properties.
Scaffold porosity may have influenced our results.
As we designed our scaffolds to have the same
global dimensions but distinct microarchitectures,
each scaffold design had a different porosity (Fig-
ure 5). After 4 weeks of implantation, the 350 lm
scaffolds had significantly higher modulus and peak
stress than 550 and 800 lm scaffolds (Table III).
However, the 350 lm scaffolds had the lowest poros-
ity (i.e. greatest volume fraction of PCL). The
increased mechanical properties of the 350 lm scaf-
folds are likely due to larger PCL volume. However,
this trend was not continued after 8 weeks so the
effect of porosity is not clear.
Also, doubling the implantation time from 4 to
8 weeks may have allowed increased tissue minerali-
zation. Total BMD was increased 8 weeks after
TABLE III




Total bone volume (mm3) 10.66 6 4.67 19.12 6 16.94 21.05 6 12.78
Scaffold bone volumea (mm3) 1.20 6 0.46b 1.64 6 0.51 2.24 6 0.57b
Total BMD (mg/cm3) 511.23 6 36.49 511.78 6 31.97 502.98 6 18.95
Scaffold BMD (mg/cm3) 477.63 6 26.95 492.44 6 44.74 479.63 6 24.67
Scaffold BVF (%) 6.24 6 2.7 6.48 6 2.1 7.96 6 2.5
Modulus (MPa)a 60.18 6 4.33b,c 32.72 6 12.56b 26.92 6 6.15c
Peak stress (MPa)a 13.54 6 3.11b,c 7.08 6 3.17b 6.92 6 2.32c
8 weeks
Total bone volume (mm3) 16.14 6 8.13 13.78 6 5.15 14.75 6 5.26
Scaffold bone volume (mm3) 2.13 6 1.56 2.21 6 1.05 2.09 6 0.61
Total BMD (mg/cm3) 545.76 6 26.43 548.42 6 22.65 561.96 6 33.86
Scaffold BMD (mg/cm3) 498.34 6 28.88 506.10 6 24.00 493.55 6 20.07
Scaffold BVF (%) 10.33 6 7.3 8.25 6 3.5 7.24 6 2.2
Modulus (MPa) 41.84 6 23.10 28.14 6 9.49 58.14 6 73.51
Peak stress (MPa) 9.42 6 4.99 6.94 6 5.34 6.82 6 6.47
aData is significantly different between seeded scaffolds with different microarchitectures at either time point (p < 0.05).
b,c,dPost hoc analysis identifying significant differences in bone regeneration and mechanical properties between scaf-
folds with different microarchitectures.
TABLE IV
Effect of Cells on Scaffold Mechanical Properties 4 and 8 Weeks After Implantation
Cells















Seeded (Cells) 60.18 6 4.33 13.54 6 3.11 32.72 6 12.56 7.08 6 3.17 26.92 6 6.15 6.92 6 2.32
Control (No Cells) 61.36 6 9.92 13.53 6 3.69 60.56 6 11.23 9.18 6 0.93 45.14 6 8.44 10.03 6 1.95
8 weeks
Seeded (Cells) 41.84 6 23.10 9.42 6 4.99 28.14 6 9.49 6.94 6 5.34 58.14 6 73.51 6.82 6 6.47
Control (No Cells) 128.19 6 93.35 32.35 6 22.00 52.10 6 6.00 10.60 6 1.82 61.89 6 49.91 9.60 6 2.21
aData is significantly different between seeded (Cells) and control (No Cells) scaffolds at either time point (p < 0.05).
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implantation compared to 4 weeks in 550- and 800-
lm seeded scaffolds (Table V); however, a corre-
sponding increase in modulus and peak stress was
not observed.
The addition of cells decreased scaffold mechani-
cal properties over time. The 550 and 800 lm control
scaffolds had a higher modulus compared to seeded
scaffolds at 4 weeks, and this trend continued for
550 lm scaffolds at 8 weeks (Table IV). The seeded
scaffold mechanical properties may have decreased
if the HGFs induced PCL degradation and conse-
quently scaffold weakening. HGF-induced PCL deg-
radation would likely become more pronounced in
scaffolds implanted for time periods longer than
8 weeks, but further study is necessary to determine
the extent of PCL degradation in our tissue engineer-
ing model.
Control scaffolds maintained mechanical proper-
ties after 4 and 8 weeks in vivo. Thus, control scaf-
folds did not seem to degrade significantly during
this time period. However, control scaffolds could
degrade if implanted for time periods longer than
8 weeks, as the reported degradation time for PCL
scaffolds ranges between 21 days to 2 years.31,32 The
degradation rate is affected by many parameters,
including fabrication technique, scaffold design,
implant location, and addition of cells and/or bio-
logical factors.
In our tissue engineering model, the majority of
bone grew outside the scaffold as observed in previ-
ous studies.12,19 However, there was some bone in-
growth within the pore space, and this model should
be refined to increase the quantity of bone in-
growth. Scaffold bone volume was significantly
increased in 800 lm scaffolds compared to 350 lm
scaffolds after 4 weeks of implantation (Table III).
After 8 weeks, scaffold bone volume for all scaffold
microarchitectures was similar. Together, the results
at 4 and 8 weeks suggest that pore sizes between
350 and 800 lm in PCL scaffolds have a limited
effect on bone regeneration. Similar results were pre-
viously demonstrated by Schek et al.,19 who found
that pore sizes of 300 and 800 lm did not affect
bone regeneration in PPF/b-TCP scaffolds.
Bone regeneration in scaffolds with pore sizes
smaller than 350 lm is variable. In one study, cal-
cium aluminate pellets with pore sizes ranging
between 10 and 200 lm were implanted into dog
femurs.16 Pore sizes between 100 and 200 lm
resulted in bone in-growth, while pore sizes between
10 and 100 lm resulted in fibrous tissue or unminer-
alized osteoid in-growth.16 In contrast, when tita-
nium plates with pore sizes of 50, 75, 100, or 125 lm
were implanted into rabbit femurs, no differences in
bone in-growth were observed between pore sizes.33
A more recent study found that PCL scaffolds with
pore sizes between 186 and 200 lm were best for
fibroblast infiltration, whereas scaffolds with pore
sizes between 290 and 310 lm showed the fastest
bone formation.15 Although we found that pore sizes
between 350 and 800 lm did not affect bone in-
growth, scaffolds with pore sizes smaller than
350 lm exhibit varying degrees of bone in-growth.
Thus, the influence of smaller pore sizes on bone
TABLE V
Effect of Scaffold Implantation Time on Bone




Scaffold pore size (350 lm)
Total bone volume (mm3) 10.66 6 4.67 16.14 6 8.13
Scaffold bone volume (mm3) 1.20 6 0.46 2.13 6 1.56
Total BMD (mg/cm3) 511.23 6 36.49 545.86 6 26.43
Scaffold BMD (mg/cm3) 477.63 6 26.95 498.34 6 28.88
Scaffold BVF (%) 6.24 6 2.7 10.33 6 7.3
Modulus (MPa) 60.18 6 4.33 41.84 6 23.10
Peak stress (MPa) 13.54 6 3.11 9.42 6 4.99
Scaffold pore size (550 lm)
Total bone volume (mm3) 19.12 6 16.94 13.78 6 5.15
Scaffold bone volume (mm3) 1.65 6 0.51 2.21 6 1.05
Total BMDa (mg/cm3) 511.78 6 31.97 548.42 6 22.65
Scaffold BMD (mg/cm3) 492.44 6 44.74 506.10 6 24.00
Scaffold BVF (%) 6.48 6 2.1 8.25 6 3.5
Modulus (MPa) 32.72 6 12.56 28.14 6 9.49
Peak stress (MPa) 7.08 6 3.17 6.94 6 5.34
Scaffold pore size (800 lm)
Total bone volume (mm3) 21.05 6 12.78 14.75 6 5.26
Scaffold bone volume (mm3) 2.24 6 0.57 2.09 6 0.61
Total BMD (mg/cm3)a 502.98 6 18.95 561.96 6 33.86
Scaffold BMD (mg/cm3) 479.63 6 24.67 493.55 6 20.07
Scaffold BVF (%) 7.96 6 2.5 7.24 6 2.2
Modulus (MPa) 26.92 6 6.15 58.14 6 73.51
Peak stress (MPa) 6.92 6 2.32 6.82 6 6.47
aData is significantly different between scaffolds im-
planted for 4 or 8 weeks for a given pore size (p < 0.05).
Figure 5. Porosity of 350, 550, and 800 lm scaffolds.
*Indicates a statistically significant difference in porosity
(p < 0.05).
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in-growth is unclear, and is likely affected by several
factors, including biomaterial, fabrication technique,
scaffold design, implant location, and addition of
cells and/or biological factors.
We observed a small amount of new bone in-
growth in seeded scaffolds. As we used an ex vivo
strategy developed previously in our lab,34 we
expected to see higher amounts of bone in-growth.
A possible reason for the small amount of in-growth
is that we implanted scaffolds into subcutaneous
pockets. If the scaffolds had been implanted into
muscle or an orthotopic site, we may have seen bet-
ter results. However, our tissue engineering model
generated new bone growth in an ectopic site, which
suggests that our model is more robust than ortho-
topic tissue engineering models.
Another possible reason for the small amount of
bone in-growth is that we used a rigorous bone
threshold of 1100 ADU in our lCT analysis to char-
acterize mineralized bone. Thus, we excluded imma-
ture bone that was not completely mineralized after
4 or 8 weeks in vivo. Analysis of scaffolds implanted
for longer than 8 weeks may determine if bone in-
growth increases with implantation time.
In conclusion, we found that (1) modulus and
peak stress of the scaffold/bone constructs depended
on pore size at 4 weeks but not at 8 weeks, (2) bone
growth inside pores depended on pore size at
4 weeks but not at 8 weeks, and (3) the length of im-
plantation time had a limited effect on scaffold/bone
construct properties. Therefore, pore sizes between
350 and 800 lm play a limited role in bone regenera-
tion in this tissue engineering model. It may be ad-
vantageous to explore the effects of other scaffold
structural properties, such as pore shape, pore inter-
connectivity, or scaffold permeability, on bone regen-
eration when designing PCL scaffolds for bone tissue
engineering.
The authors thank Alisha Diggs and Colleen Flanagan
for help with scaffold fabrication, and Darice Wong, Elly
Liao, and John Kemppainen for help with animal sur-
geries.
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